Summary
We have tested the in-vitro activities of BAY y 3118, a new chlorofluoroquinolone, ciprofloxacin, sparfloxacin, streptomycin, tetracycline and rifampin against 59 strains of Brucella melhensis. BAY y 3118 (MIC90, 0.12 mg/L) was twice as active as sparfloxacin and tetracycline (MIC90 0.25 mg/L). The activity of ciprofloxacin, rifampin and streptomycin (MIC90, 0.5, 2, and 8 mg/L, respectively) was, respectively, four-, sixteen-, and more than sixty-fold lower than that of BAY y 3118.